DDInter593 DDInter740
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Doxepin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Doxepin {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Doxepin {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Doxepin {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Metoclopramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Doxepin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Doxepin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Doxepin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Doxepin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Doxepin (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)